ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag biobusiness cancer fda genetics genomics

A vet and technician take a sample from a dog for use in PetDx’s OncoK9 test, which screens cell-free DNA for genomic alterations associated with cancer.
The Pet Health Industry Takes on Canine Cancer
Diana Kwon | Oct 17, 2022 | 9 min read
Advanced genomic tools have provided biotech companies new approaches to help our furry friends—but experts say several limitations remain.
Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020 | 8 min read
There’s a new cell-based cancer immunotherapy on the block.
Diagnosing Cancer: A Genomics and Proteomics Approach
Tom Hollon | Sep 21, 2003 | 7 min read
In 1996, Jeff Trent and colleagues published the first paper describing DNA microarrays as tools for pinpointing gene variants underlying various tumor properties.1 Now, as president and scientific director of Translational Genomics Research Institute (TGEN), in Phoenix, Trent is using microarrays to look for gene expression patterns that can be applied to developing diagnostics. The role of microarrays, Trent says, "will be on the discovery side. Testing all 30,000 genes against a diagnosti
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Braving the IPO Drought
Megan Scudellari | Mar 1, 2012 | 7 min read
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.
Those We Lost in 2018
Ashley Yeager | Dec 26, 2018 | 10+ min read
The scientific community said goodbye to a number of leading researchers this year.
The Rise of Free, Global Gene Expression Data Sets
Jim Kling | Apr 1, 2002 | 5 min read
See related Techlink, "The Data Analysis Grand Prix". For this article, Jim Kling interviewed Patrick O. Brown, Howard Hughes Medical Institute investigator and professor in the department of biochemistry, Stanford University Medical School in Stanford, Calif., and John N. Weinstein, senior investigator at the National Cancer Institute and head of the genomics and bioinformatics group, in Bethesda, Md. Data from the Web of Science show that Hot Papers are cited 50 to 100 times more often than t

Run a Search

ADVERTISEMENT